Compare DTI & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | NSRX |
|---|---|---|
| Founded | 1984 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 63.4M |
| IPO Year | N/A | 2025 |
| Metric | DTI | NSRX |
|---|---|---|
| Price | $2.83 | $6.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | ★ 113.5K | 3.5K |
| Earning Date | 11-06-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,964,000.00 | N/A |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $1.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $1.43 | $5.90 |
| 52 Week High | $3.82 | $9.99 |
| Indicator | DTI | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | N/A |
| Support Level | $2.70 | N/A |
| Resistance Level | $2.95 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 53.95 | 0.00 |
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.